Liver diseases: epidemiology, causes, trends and predictionsCan Gan, Jia Xiao, Yuan Yuan et al.|Signal Transduction and Targeted Therapy|2025Cited by 205
1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trialHui‐Chuan Sun, Xiao‐Dong Zhu, Tianqiang Song et al.|Annals of Oncology|2025Cited by 3